



Date: 03-02-2023

To,
The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001.
Scrip Code : 524518

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd,
Exchange Plaza, Bandra Kurla Complex,
Bandra(E), Mumbai- 400051.
Scrip Code : KREBSBIO

Dear Sir / Madam,

Sub: Outcome of Board Meeting under Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015:

Further to our letter dated January 23, 2023 and in compliance with Regulation 30 read with Schedule III and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, we wish to inform that the Board of Directors of the Company at its meeting held today have approved the following:

1. Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022 along with the Limited Review Report by the Statutory Auditors thereon - Enclosed.
2. Appointment of Mr. Rohit Taparia as Company Secretary & Compliance Officer and Key Managerial Personnel of the Company with effective from February 3, 2023. Enclosed is details of the Company Secretary appointed.
3. Appointment of Mr. Ritesh Jain as Chief Financial Officer (CFO) and Key Managerial Personnel of the Company with effective from February 3, 2023. Enclosed is details of the CFO appointed.



4. Resignation of Mr. Ravi Babu as Chief Financial Officer and Key Managerial Personnel of the Company from the closure of business hours on February 3, 2023. Details of the resigned CFO is as below:

1	Name	Mr. Ravi Babu
2	Designation	Chief Financial Officer
3	Reason for change	Resigned from Employment
4	Date of cessation	February 3, 2022
5	Brief Profile	NA
6	Disclosure of Relationship between Directors (in case of appointment of a Director)	NA

5. The Board has decided to maintain the registers, book of accounts and other documents as required to be maintained under the provisions of Companies Act, 2013 at Registered Office of the Company situated at Kothapalli (V), Kasimkota (M), Anakapalli, Visakhapatnam, Andhra Pradesh-531 031 w.e.f 1st April, 2023 from Corporate Office situated at 8-2-577/B, Plot No. 34, 3rd Floor, Maas Heights, Road No. 8, Banjara Hills, Hyderabad-500 034, Andhra Pradesh subject to the approval of shareholders. Postal Ballot Notice shall be shared in due course.


The Meeting of the Board of Directors commenced at 12:30 p.m. and concluded at 03:20 p.m.

The above is for your information and record.

Thanking you,

Yours Faithfully

For **Krebs Biochemicals and Industries Limited**



Pabitrakumar Bhattacharyya
Managing Director

Email:com_sec@krebsbiochem.com

Encl: as above

Annexure – II

The continuous disclosure requirement under regulation 30 pursuant to SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015.

Sl. No	Particulars	Details
1	Reason for change	Appointment of Mr. Ritesh Jain as Chief Financial Officer (CFO) and Key Managerial Personnel of the Company due to resignation of Mr. Ravi Babu, CFO.
2	Date of appointment & term of appointment	February 3, 2023 and terms as decided by Board of Directors
3	Brief profile (in case of appointment)	Mr. Ritesh Jain is a Chartered Accountant with more than 19 years of extensive experience in Accounts Finalization, Direct & Indirect Taxation, Audit – Statutory & internal, management Reporting and Analysis, Project profitability and variance analytics, preparation of budget and variance analysis, Direct Taxation & GST and General Accounting & Reporting. In addition he has proven skills in managing Service Delivery, Client Relationships and Transformation. Before that he was associated with Nahar Builders.
4	Disclosure of relationships between directors (in case of appointment of a director).	Mr. Ritesh Jain is not related to any Directors of the Company.

